SelectImmune Pharma Interim report Q3 2021/2022
SELECTIMMUNE PHARMA IN SHORT · SelectImmune Pharma is an innovative biotech company, developing novel immunotherapies. · Excessive innate immune responses to infection cause symptoms and pathology in acute pyelonephritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these conditions as alternatives or complements to antibiotics. · Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. · One drug candidate,